CMPS
NASDAQCOMPASS Pathways Plc
Price$11.78+0.07 (+0.64%)
01:30 PM01:45 PM
News · 26 weeks59+17%
2025-12-142026-06-07
Mix4290d
- Insider14(33%)
- Other11(26%)
- SEC Filings8(19%)
- Offering5(12%)
- Analyst3(7%)
- Earnings1(2%)
Latest news
25 items- PRCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company's American Depositary Shares on the Nasdaq Globa
- INSIDERSEC Form 4 filed by Director Karydas Daphne4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Santini Gino4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Gover Justin D.4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Jonas Jeffrey M4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Riley Wayne Joseph4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcquade Robert4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Norton David Y4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Tregoning Kathleen4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tregoning Kathleen3 - COMPASS Pathways plc (0001816590) (Issuer)
- SECSEC Form 8-K filed by COMPASS Pathways Plc8-K - COMPASS Pathways plc (0001816590) (Filer)
- PRCompass Pathways Elects Kathleen Tregoning to Board of DirectorsCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a
- PRCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are moti
- ANALYSTWolfe Research initiated coverage on COMPASS PathwaysWolfe Research initiated coverage of COMPASS Pathways with a rating of Outperform
- SECAmendment: SEC Form SCHEDULE 13G/A filed by COMPASS Pathways PlcSCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)
- PRCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in men
- SECCOMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - COMPASS Pathways plc (0001816590) (Filer)
- SECSEC Form 10-Q filed by COMPASS Pathways Plc10-Q - COMPASS Pathways plc (0001816590) (Filer)
- PRCompass Pathways Announces First Quarter 2026 Financial Results and Business HighlightsFDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, expected in early Q3 2026 Final NDA submission on track for Q4, aligned with Company's previously defined accelerated timing to be launch ready by end of year Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028 Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today re
- PRCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NA
- PRCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 59,625 shares. The options have an exercise price per share equal to $9.01, the closing price of the Company's American Depositary Shares on the Nasdaq Global S
- ANALYSTJefferies initiated coverage on COMPASS Pathways with a new price targetJefferies initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $18.00
- PRCompass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority VoucherCompass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standards FDA grants Compass NDA rolling submission and review request, based on Phase 3 data CNPV awarded for COMP360, Compass' proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD) CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S
- ANALYSTB. Riley Securities initiated coverage on COMPASS Pathways with a new price targetB. Riley Securities initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $17.00
- PRCompass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic TreatmentsCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind i
CMPS FAQ
7 questionsWhat does COMPASS Pathways Plc do?
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.Where does CMPS stock trade?
COMPASS Pathways Plc (CMPS) is listed on NASDAQ.What sector and industry is CMPS in?
COMPASS Pathways Plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did COMPASS Pathways Plc go public?
COMPASS Pathways Plc (CMPS) completed its IPO in 2020.What are analysts saying about CMPS?
COMPASS Pathways Plc has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-05-22. Recent price targets range from $600.00 to $3000.00.What companies are similar to CMPS?
Notable peers in the same industry include ATAI (AtaiBeckley Inc.), CODI (D/B/A Compass Diversified Holdings Shares of Beneficial Intere), CMPX (Compass Therapeutics Inc.). Compare CMPS side-by-side with any of them on Quantisnow.How can I track CMPS on Quantisnow?
Quantisnow aggregates COMPASS Pathways Plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMPS to receive live email and push alerts on every new disclosure.